Inhibrx Biosciences (INBX) Income towards Parent Company: 2023-2025
Historic Income towards Parent Company for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$35.3 million.
- Inhibrx Biosciences' Income towards Parent Company rose 19.62% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 109.44%. This contributed to the annual value of $1.7 billion for FY2024, which is 803.96% up from last year.
- Per Inhibrx Biosciences' latest filing, its Income towards Parent Company stood at -$35.3 million for Q3 2025, which was down 23.04% from -$28.7 million recorded in Q2 2025.
- Inhibrx Biosciences' Income towards Parent Company's 5-year high stood at $1.9 billion during Q2 2024, with a 5-year trough of -$92.0 million in Q4 2023.
- In the last 3 years, Inhibrx Biosciences' Income towards Parent Company had a median value of -$45.9 million in 2024 and averaged $138.8 million.
- As far as peak fluctuations go, Inhibrx Biosciences' Income towards Parent Company spiked by 3,898.37% in 2024, and later crashed by 101.54% in 2025.
- Quarterly analysis of 3 years shows Inhibrx Biosciences' Income towards Parent Company stood at -$92.0 million in 2023, then skyrocketed by 47.96% to -$47.9 million in 2024, then increased by 19.62% to -$35.3 million in 2025.
- Its last three reported values are -$35.3 million in Q3 2025, -$28.7 million for Q2 2025, and -$43.3 million during Q1 2025.